Navigation Links
Open Biosystems' Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina

Genome scale RNAi analysis affordable and accessible to all researchers

HUNTSVILLE, Ala., March 11 /PRNewswire/ -- Open Biosystems, Inc. announced today that Harvard Medical School and the University of North Carolina have joined the Open Access(TM) RNAi Program. Each University purchased access to whole genome human and mouse lentiviral shRNA libraries developed by The RNAi Consortium and distributed by Open Biosystems.

(Logo: )

Tal Kafri M.D. Ph.D., Associate Professor in the Department of Microbiology and Immunology at the Gene Therapy Center, said, "Open Biosystems' Open Access Program empowers all researchers at the University of North Carolina with the ultimate promise of RNAi by offering unrestricted access to genome scale RNAi resources. From knockdown of single genes to pathway and whole genome RNAi screening with lentiviral shRNA, this program will definitely accelerate the pace of discovery at UNC."

"They are a welcome addition to the collaborative network of investigators worldwide implementing the latest advancements in shRNA technologies," said Troy Moore, Chief Technical Officer. "Participation in the Open Access Program enables investigators throughout these institutions to access their choice of Open Biosystems' unique portfolio of genome-wide RNAi resources."

Open Biosystems' portfolio of RNAi resources include shRNAmir lentiviral and retroviral libraries targeting the entire human and mouse genomes, The RNAi Consortium human and mouse lentiviral shRNA libraries and RNAi libraries targeting Drosophila, C. elegans and Arabidopsis thaliana. Participation in the Open Access RNAi program provides researchers the most complete and flexible access to their choice of these rapidly evolving RNAi technologies.

About Open Access RNAi

The Open Biosystems Open Access RNAi Program gives entire academic systems, including multiple campuses, access to the company's advanced RNAi libraries, priority technical support, and continued access to all extensions of existing libraries as well as library upgrades. In this manner, Open Biosystems supports academic research without imposing heavy financial burdens on individual labs. The program is customizable and can be tailored to fit the diverse needs of research institutions worldwide. Complete details can be found at

About Open Biosystems

Open Biosystems, Inc. develops, manufactures and markets genomic research tools to scientists and researchers in corporate, academic and government laboratories. These research tools provide investigators with standardized high-quality genes, RNAi and antibodies for interrogating gene function in relation to oncology, neuroscience and metabolic disorders. Founded in 2001, Open Biosystems is headquartered in Huntsville, Alabama. For more information and details for ordering, please visit

SOURCE Open Biosystems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich, Oxford BioMedica and Open Biosystems Settle Patent Dispute Over Use of LentiVector Technology in Research Reagents
2. Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System
3. Primera Biosystems Raises $21 Million in Series B Private Round
4. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
5. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
6. Singulex Collaborates With Large Pharmaceutical Company in Erenna(TM) Technology Access Program
7. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Johns Hopkins Bayview at Forefront of Expanding Access to MRI With First Install of Siemens New MAGNETOM Verio
9. Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access
10. Access Pharmaceuticals Announces $2.7 Million New Equity
11. Clinical and Economical Considerations For IV Push Drug Delivery by Industry Expert Richard Rosenfeld Is Now Accessible on for Media and Professional Use
Post Your Comments:
(Date:11/25/2015)... 25, 2015 Studies reveal the ... plaque and pave the way for more effective treatment for ...     --> --> ... health problems in cats, yet relatively little was understood about ... studies have been conducted by researchers from the WALTHAM Centre ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, Inc. ... participate in a fireside chat discussion at the Piper ... York . The discussion is scheduled for Wednesday, ... .  A replay will be available for ... Stilwell  , Julie NormartVP, Corporate Communications and Business ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - Aeterna ... request of IIROC on behalf of the Toronto Stock ... news release there are no corporate developments that would ... --> --> About ... . --> Aeterna Zentaris is ...
Breaking Biology Technology:
(Date:10/29/2015)... ANN ARBOR, Mich. , Oct. 29, 2015 ... with Eurofins Genomics for U.S. distribution of its ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq ... DNA to enable the preparation of NGS libraries ... in plasma for diagnostic and prognostic applications in ...
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... a partnership with 2XU, a global leader in ... a smart hat with advanced bio-sensing technology. The ... athletes to monitor key biometrics to improve overall ... partnership, the two companies will bring together the most ...
(Date:10/27/2015)... Oct. 27, 2015 Synaptics Inc. (NASDAQ: SYNA ... that Google has adopted the Synaptics ® ClearPad ... to power its newest flagship smartphones, the Nexus 5X ... --> --> Synaptics ... provide strategic collaboration in the joint development of next ...
Breaking Biology News(10 mins):